Terragen raises $7M to cccelerate biotech expansion
Australian biotech firm Terragen (ASX:TGH) announced binding commitments for a $7 million equity raising.
The capital injection, achieved through the issuance of new fully paid ordinary shares at $0.022 each, marks a pivotal moment for the company as it seeks to validate its product range.
The funding structure is bifurcated into two distinct tranches. The first involves an institutional placement of approximately $2.8 million utilising the company’s existing placement capacity.
The second, a conditional placement of $4.2 million, is subject to shareholder approval.
Non-executive Director Scobie Ward has demonstrated strong internal confidence by committing $2.3 million to the raising.
The capital boost significantly enhances Terragen's financial standing, bringing its pro forma cash position to approximately $9.8 million as of late 2025.
The proceeds are earmarked for high-impact initiatives: advancing research and development to diversify their biological product offerings and scaling their commercial footprint internationally.
More from Australia
Woodside Energy cuts 500 jobs to slash costs by US$570M
NSW panel recommends 26 stricter data centre rules
Top End Energy applies to surrender permit EP 153
Neuren Pharmaceuticals upgrades full year guidance
Vicinity Centres places earnings guidance under review
Resources & Energy expands Menzies Project by 69%
